Fracture definitions in observational osteoporosis drug effects studies that leverage healthcare administrative (claims) data: a scoping review.


Journal

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 15 12 2021
accepted: 30 03 2022
pubmed: 17 5 2022
medline: 14 9 2022
entrez: 16 5 2022
Statut: ppublish

Résumé

Healthcare administrative (claims) data are commonly utilized to estimate drug effects. We identified considerable heterogeneity in fracture outcome definitions in a scoping review of 57 studies that estimated osteoporosis drug effects on fracture risk. Better understanding of the impact of different fracture definitions on study results is needed. Healthcare administrative (claims) data are frequently used to estimate the real-world effects of drugs. Fracture incidence is a common outcome of osteoporosis drug studies. We aimed to describe how fractures are defined in studies that use claims data. We searched MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCO), and gray literature for studies published in English between 2000 and 2020 that estimated fracture effectiveness (hip, humerus, radius/ulna, vertebra) or safety (atypical fracture of the femur, AFF) of osteoporosis drugs using claims data in Canada and the USA. Literature searches, screening and data abstraction were completed independently by two reviewers. We identified 57 eligible studies (52 effectiveness, 3 safety, 2 both). Hip fracture was the most common fracture site studied (93%), followed by humerus (66%), radius/ulna (59%), vertebra (61%), and AFF (9%). Half (n = 29) of the studies did not indicate specific data sources, codes, or cite a validation paper. Of the papers with sufficient detail, heterogeneity in fracture definitions was common. The most common definition within each fracture site was used by less than half of the studies that examined effectiveness (12 definitions in 29 hip fracture papers, 8 definitions in 17 humerus papers, 8 definitions in 13 radius/ulna papers, 9 definitions in 15 vertebra papers), and 3 definitions among 4 AFF papers. There is ambiguity and heterogeneity in fracture outcome definitions in studies that leverage claims data. Better transparency in outcome reporting is needed. Future exploration of how fracture definitions impact study results is warranted.

Identifiants

pubmed: 35578134
doi: 10.1007/s00198-022-06395-x
pii: 10.1007/s00198-022-06395-x
pmc: PMC9463274
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1837-1844

Informations de copyright

© 2022. The Author(s).

Références

Am Fam Physician. 2015 Aug 15;92(4):261-8
pubmed: 26280231
Osteoporos Int. 2011 May;22(5):1335-42
pubmed: 20577872
JAMA. 2018 Sep 4;320(9):867-868
pubmed: 30105359
J Clin Densitom. 2012 Jan-Mar;15(1):92-102
pubmed: 22071028
J Bone Miner Res. 2005 Apr;20(4):557-63
pubmed: 15765173
Bone. 2007 Nov;41(5):882-7
pubmed: 17707710
J Clin Epidemiol. 2017 Apr;84:150-160
pubmed: 28017849
Can J Hosp Pharm. 2015 May-Jun;68(3):232-7
pubmed: 26157185
JBI Evid Synth. 2021 Oct 11;20(3):907-916
pubmed: 34636342
Clin Exp Rheumatol. 2015 May-Jun;33(3):302-9
pubmed: 25068266
J Bone Miner Res. 2011 Mar;26(3):553-60
pubmed: 20814954
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Int J Popul Data Sci. 2020 Mar 11;4(2):1135
pubmed: 32935037
Osteoporos Int. 2014 Oct;25(10):2359-81
pubmed: 25182228
JAMA. 2011 Feb 23;305(8):783-9
pubmed: 21343577
Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1018-1032
pubmed: 28913963
Perspect Health Inf Manag. 2011;8:1c
pubmed: 22016669
BMC Public Health. 2012 May 18;12:301
pubmed: 22537071
Ann Intern Med. 2008 May 6;148(9):637-46
pubmed: 18458276
J Bone Miner Res. 2019 Oct;34(10):1798-1807
pubmed: 31170317
J Manag Care Spec Pharm. 2015 Jan;21(1):56-65
pubmed: 25562773
Osteoporos Int. 2019 Jan;30(1):3-44
pubmed: 30324412
Med Care. 2009 Jan;47(1):69-72
pubmed: 19106733
CMAJ Open. 2013 Sep 13;1(3):E97-E105
pubmed: 25077113
CMAJ. 2010 Nov 23;182(17):1864-73
pubmed: 20940232
J Med Libr Assoc. 2017 Jul;105(3):285-289
pubmed: 28670219
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
J Clin Epidemiol. 2008 Dec;61(12):1250-1260
pubmed: 18619800
Osteoporos Int. 2013 Feb;24(2):659-69
pubmed: 22736067
J Clin Epidemiol. 2011 Jan;64(1):46-53
pubmed: 21130353
J Clin Epidemiol. 1992 Jul;45(7):703-14
pubmed: 1619449

Auteurs

N Konstantelos (N)

Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada. n.konstantelos@mail.utoronto.ca.

A M Rzepka (AM)

Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.

A M Burden (AM)

Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
ETH Zurich, Zurich, Switzerland.

A M Cheung (AM)

Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Department of Medicine, University Health Network, University of Toronto, Toronto, Canada.

S Kim (S)

Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
Women's College Hospital, Toronto, Canada.

P Grootendorst (P)

Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
WHO Collaborating Centre for Governance, Accountability and Transparency in the Pharmaceutical Sector, Toronto, Canada.

S M Cadarette (SM)

Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
WHO Collaborating Centre for Governance, Accountability and Transparency in the Pharmaceutical Sector, Toronto, Canada.
Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH